Data by Company within Laboratory Analytical Instruments Industry
|
| |
Marketcap |
Revenues (TTM) |
Net Income (TTM) |
Employees |
| Company |
(Millions) |
(Millions) |
(Millions) |
Number |
| Agilent Technologies inc |
$ 32,866 |
$ 6,994 |
$ 1,133 |
18,100 |
| Mettler Toledo International Inc |
$ 24,289 |
$ 3,954 |
$ 889 |
17,800 |
| Illumina Inc |
$ 21,058 |
$ 4,656 |
$ 701 |
9,800 |
| Avantor Inc |
$ 14,256 |
$ 7,176 |
$ 423 |
- |
| Revvity Inc |
$ 13,731 |
- |
$ 428 |
- |
| Bio rad Laboratories Inc |
$ 10,363 |
$ 2,768 |
$ -424 |
7,900 |
| Bruker Corporation |
$ 9,188 |
$ 2,714 |
$ 322 |
6,900 |
| 10x Genomics Inc |
$ 4,826 |
$ 525 |
$ -220 |
1,500 |
| Pacific Biosciences Of California Inc |
$ 2,236 |
$ 146 |
$ -319 |
500 |
| Olink Holding Ab publ |
$ 1,714 |
$ 95 |
$ -38 |
267 |
| Quanterix Corp |
$ 934 |
$ 107 |
$ -61 |
359 |
| Cytek Biosciences Inc |
$ 867 |
$ 175 |
$ -6 |
300 |
| Misonix Inc |
$ 458 |
$ 74 |
$ -14 |
- |
| Nautilus Biotechnology Inc |
$ 397 |
- |
$ -58 |
- |
| Eyepoint Pharmaceuticals Inc |
$ 318 |
$ 37 |
$ -106 |
- |
| Standard Biotools Inc |
$ 219 |
$ 105 |
$ -84 |
- |
| Scientific Industries Inc |
$ 208 |
$ 11 |
$ -8 |
739 |
| Akoya Biosciences Inc |
$ 180 |
$ 85 |
$ -76 |
- |
| Harvard Bioscience Inc |
$ 173 |
$ 114 |
$ -5 |
289 |
| Seer Inc |
$ 146 |
$ 16 |
$ -94 |
- |
| Precipio inc |
$ 136 |
$ 11 |
$ -11 |
- |
| Phenomex Inc |
$ 98 |
$ 72 |
$ -125 |
- |
| Bionano Genomics Inc |
$ 92 |
$ 32 |
$ -147 |
- |
| Cue Health Inc |
$ 70 |
$ 251 |
$ -276 |
51 |
| Accelerate Diagnostics Inc |
$ 62 |
$ 12 |
$ -80 |
- |
| Kewaunee Scientific Corporation |
$ 50 |
$ 218 |
$ 5 |
1,357 |
| Rapid Micro Biosystems Inc |
$ 49 |
$ 19 |
$ 29 |
- |
| Prenetics Global Limited |
$ 36 |
$ 276 |
$ -190 |
- |
| Isoplexis Corporation |
$ 30 |
$ 17 |
$ -106 |
- |
| Singular Genomics Systems Inc |
$ 28 |
- |
$ 88 |
- |
| Astrotech Corp |
$ 17 |
$ 0 |
$ -9 |
42 |
| Talis Biomedical Corporation |
$ 10 |
$ 3 |
$ -86 |
- |
| Lifeloc Technologies Inc |
$ 8 |
$ 9 |
$ 0 |
- |
| Reflect Scientific Inc |
$ 6 |
$ 1 |
$ -1 |
- |
| Pressure Biosciences Inc |
$ 4 |
$ 2 |
$ -26 |
- |
| Thermogenesis Holdings Inc |
$ 3 |
$ 9 |
$ -15 |
- |
| Htg Molecular Diagnostics Inc |
$ 1 |
$ 6 |
$ -20 |
- |
| Codex Dna Inc |
- |
$ 7 |
$ -19 |
- |
| Laboratory Analytical Instruments Industry |
$ 139,126 |
$ 30,696 |
$ 1,392 |
65,904 |
Recent News from Laboratory Analytical Instruments Industry |
|
Dividend
Agilent Technologies, Inc. (NYSE: A), a global leader in analytical and clinical laboratory solutions, recently announced a quarterly cash dividend of 22.5 cents per share of common stock. The dividend is expected to be paid on October 25, 2023, to all shareholders of record as of October 3, 2023. While the company continues to face challenges, this announcement reflects Agilent's commitment to rewarding its shareholders amidst a fluctuating stock performance.
Agilent Technologies, Inc. (NYSE: A), headquartered in Santa Clara, California, specializes in the development, manufacturing, and marketing of analytical instruments, software, services, and consumables. The company's comprehensive portfolio is utilized by scientists and researchers across various industries, including life sciences, diagnostics, and applied chemical markets.
|
|
|
Kewaunee Scientific Corporation
Kewaunee Scientific Corporation, a prominent Laboratory Analytical Instruments company, recently released its financial results for the fiscal first quarter of 2024. Despite a decline in revenue, the company managed to achieve profitability, indicating certain positive developments for shareholders. This article will analyze the financial results and examine how they may impact the company's future.
1. Revenue Decline:
Kewaunee Scientific Corporation experienced a decrease in revenue by -2.412% to $48.91 million compared to the previous year. This decline can pose challenges, as it signifies a potential slowdown in sales growth. However, it is essential to consider the reasons behind the drop in revenue, aiming to identify any temporary or fixable issues affecting Kewaunee's performance.
|
|
|
Agilent Technologies Inc
Agilent Technologies Inc. experienced a modest increase in its stock price over the last five trading days, rising by 1.16%. However, this gain must be put into perspective, as the year-to-date performance of the stock is at -19.31%. Investors should evaluate this recent uptick in light of the overall downward trend in the company's stock value.
One of the contributing factors to this decline is a reduction in earnings per share. Agilent Technologies Inc. saw a significant decrease of -65.45% in earnings per share, falling to $0.38. Additionally, the company witnessed a revenue decrease of -2.678% to $1.67 billion compared to the previous fiscal period.
|
|
|
Pressure Biosciences Inc
Pressure Biosciences Inc's (PBIO) financial results for the second quarter of 2023 have left analysts and investors with mixed emotions. While the company reported a surge in net deficit and a decline in inventories and accounts receivable, they managed to achieve modest revenue growth. This article will analyze PBIO's financial performance in the context of the overall Laboratory Analytical Instruments industry and the company's stock performance.
Financial Results Analysis:
PBIO reported a per-share deficit of $-0.57 for the second quarter of 2023, an increase from -$0.32 in the same quarter a year ago. Sequentially, the deficit also rose from -$0.46 per share from the prior quarter. This decline in profitability raises concerns among investors and underscores the need for PBIO to address its financial challenges.
|
|
|
Accelerate Diagnostics Inc
Accelerate Diagnostics Inc (AXDX) has reported an increase in losses for the fiscal time-frame ending June 30, 2023, primarily due to weak demand. The net loss per share advanced to $-2.97 from $-0.24, indicating a significant decline in profitability. Additionally, the company's revenue witnessed a decline of 27.506%, amounting to $2.80 million compared to $3.86 million in the previous year.
In comparison to the previous quarter, there was a slight decrease in revenue by 0.462%, from $2.81 million. Furthermore, there was a surge in loss per share from $-0.17. These figures highlight the ongoing struggles faced by Accelerate Diagnostics Inc in maintaining a stable financial performance.
For the financial time-frame ending June 30, 2023, Accelerate Diagnostics Inc recorded a net loss of $-32.735 million, surpassing the loss of $-18.523 million reported a year ago. This reflects a continuing trend of declining profitability for the company.
|
|
|
Phenomex Inc
Phenomex Inc, a company specializing in [insert industry/sector], recently released its financial results for the second quarter of 2023. The report showcases weak business performance, resulting in a rise in losses. This article aims to interpret the financial results, highlighting the implications they may have on Phenomex Inc's future prospects.
1. Substantial Losses:
The second quarter saw an increase in losses, with the shortfall per share rising from $-0.38 to $-0.51. This signals a concerning trend that the company needs to address promptly.
|
|
|
Precipio Inc
In the financial second quarter of 2023, Precipio Inc experienced a loss of $0.09 per share. However, the company's revenue saw a significant increase of 49.767% to $3.53 million compared to the same quarter in the previous year. This positive revenue growth goes against the trend in the Laboratory Analytical Instruments sector, wherein most of the industry's competitors have witnessed a contraction in their top-line figures during the same time period.
In the preceding quarter, Precipio Inc generated a revenue of $2.82 million and incurred a loss of $0.13 per share. Looking at the financial span ending June 30, 2023, the company reported a net shortfall of $2.293 million, which was slightly higher than the $2.138 million deficit recorded a year ago.
The level of inventories held by Precipio Inc is seen as an indicator of future demand, and in this case, the inventories have declined to $0.5 million at the Laboratory Analytical Instruments company compared to the previous quarter and the same period last year. This indicates a potential decrease in demand for the company's products.
|
|
|
Talis Biomedical Corporation
Talis Biomedical Corporation, a leading Laboratory Analytical Instruments company, recently released its financial results for the second quarter of the 2023 earnings season. The company reported a significant increase in the shortfall per share, which stood at $-8.27 compared to $-1.01 in the same period last year. Additionally, the shortfall surged from $-0.66 per share from the previous reporting period.
Despite the disappointing earnings, Talis Biomedical Corporation experienced gentle revenue growth of 1.573%, reaching $0.58 million from $0.57 million in the same reporting period a year ago. However, there was a sequential revenue tumble of -52.299%, dropping from $1.22 million. This unexpected performance from Talis Biomedical Corporation sets it apart from the rest of the Laboratory Analytical Instruments sector, which saw a decline of -11.43% in business.
|
|
|
Thermogenesis Holdings Inc
In a shocking turn of events, the Laboratory Analytical Instruments company released its financial report for the second quarter of 2023, revealing a significant decline in revenue and widening net deficit. Investors who had high hopes for the company's performance were left disappointed as the numbers painted a bleak picture.
The financial report highlighted a staggering 51.502% decrease in revenue, with sales plummeting to $1.47 million, compared to the corresponding period a year ago. Additionally, the net deficit per share extended to $-0.91, a significant drop from the preceding financial reporting period's net deficit of $-4.07 per share.
|
|
|
Bruker Corporation
The Laboratory Analytical Instruments industry has taken an unexpected turn with the impressive fiscal performance of Bruker Corporation. While many of its sector contemporaries experienced declines in business, BRKRsn managed to defy the trend and achieve significant revenue and income growth. In this article, we delve into the recent financial results released by the company and highlight some interesting facts.
Revenue Growth and Income Improvement:
In the fiscal span closing on June 30, 2023, Bruker Corporation showcased remarkable revenue growth. Compared to the previous year, their revenue increased by an impressive 15.823%, reaching a total of $681.50 million. This growth stands in stark contrast to the overall decline witnessed in the Laboratory Analytical Instruments sector.
|
|
|
|
|
|
